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A bstract
B inding o f viru ses to cell surface m olecules is
an essential step in viral in fection . In vitro
studies suggested that the αv β3 integrin receptor
is the epithelial cell recepto r for H an taan virus
(H TN V). W hether β3 is in vivo the only or central
cellular receptor for HTN V infection is not know n.
To investigate th e role o f β3 in tegrin fo r cellular
entry of H TN V, w e established an H TN V infection
m o del in new b orn m urin e pu ps. Infected pu ps
died at an average age of 14.2 ± 1.1 days w ith
high levels of viral antigen detected in their brain,
lung, and kidney. Pre-injection of blocking m ono clon al antibod ies (m A b) sp ecific fo r either β3 o r
αv prolo nged su rvival sig nifican tly to a m axim al
averag e su rvival o f 19.7 ± 1.5 days (P ＜ 0.01)
and 18.4 ± 0.9 d ays ( P ＜ 0.01), respectively. X T199, a chem ical blocker of the αv β3 receptor also
prolonged survival to 19.5 ± 1.3 days ( P ＜ 0.01).
In co ntrast to these recepto r b lockad es, antiH T N V antibod y w as no t on ly ab le to p ro lon g
survival, but 20% of infected pups achieved longterm survival. A n anti-m urine β1 antibody com pa ratively prolong ed survival (19.0 ± 1.2 days),
suggesting that H TN V infection is partly m ediated

throug h integrin β1 receptors as w ell as throug h
β3 recep tors in vivo . O u r data dem on strate that
the β3 recep tor is im p ortant for H TN V infection
in vivo , b ut also sug gest that H TN V m ay utilize
add itional receptors beyond β3 for cellular entry
w ith in an organism .
K eyw ords: Hantaan virus; integrin β3 ; integrin β1 ;
receptor; viral entry

In tro d u c tio n
Hantaviruses are a genus of genetically- and serologically-related viruses belonging to the family Bunyaviridae. This family includes the etiologic agents of two
distinct disease syndromes in humans, hemorrhagic
fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS), which are transmitted from
rodents to humans (Lee et al., 1978; Nichol et al.,
1993). Old World hantanviruses, such as the Hantaan
(HTN) (Asia), Seoul (worldwide), Dobrava (Europe),
Puumala (Scandinavia and western Russia), and related viruses cause HFRS, which is characterized by
fever, renal failure, thrombocytopenia and in severe
cases, hemorrhagic manifestations. New W orld hantaviruses, Sin Nombre, Andes and related viruses
(North and South America), cause HPS, which is
characterized by severe acute respiratory dystunction
and a mortality rate of approximately 50% (Nicole et
al., 1993; Song et al., 1994; Lopez et al., 1996).
Cellular receptor binding is the first step in viral
infection. Many different cell surface molecules can
serve as receptors for the attachment or entry of viruses. One commonly used receptor family utilized for
viral entry is the integrin. Viruses that utilize these
receptors include echoviruses 1, 8, 9, and 22 (Bergelson et al., 1992; Bergelson et al., 1993; Pulli et al.,
1997; Nelsen-Salz et al., 1999), coxackievirus A9 (Roivainen et al., 1994), foot-and mouse disease virus
(FMDV) (Jackson et al., 1997; Jackson et al., 2000),
papillomavirus (Evander et al., 1997), adenovirus (Wickham et al., 1993), adeno-associated virus type 2 (Summerford et al., 1999), and rotavirus (Coulson et al., 1997).
Recent data have demonstrated that integrins containing the β3 chain may also be involved in the
cellular entry of hantavirus (Gavrilovskaya et al.,
1998; 1999). However, to date, there is no strong
evidence to indicate that this mechanism of cellular
entry of hantavirus is of biological relevance in vivo.
In the present studies, we establish a newborn murine
model for HTN virus (HTNV) infection and show that
β3 -containing integrins play a part in efficient HTNV
infection in this model.
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M a terials a n d M eth o d s
Virus
HTNV (strain 76-118) and Prospect Hill virus (PHV,
strain 405), were propagated in Vero E6 cells (W T,
Vero C1008; ATCC CRL 1586 USA), maintained in
Dulbecco's modified Eagle's medium supplemented
with 5% heat-inactivated fetal bovine serum (FBS), 2
mM L-glutamine, and antibiotics (100 µg/L gentamycin)
o
(Life Technologies, Inc.) at 37 C, 5% CO 2 incubator.
Quantitative virus titers were measured by counting
plaques on Vero E6 cell monolayers, as previously
described (White et al., 1982). For animal inoculation,
dilutions of virus stock (1.5×10 7 PFU) were made in
phosphate buffered salaine (PBS, pH 7.4, Life Technologies, Inc.) containing a final concentration of
0.75% bovine albumin and stored in aliquots at -80 oC
until used.
M urine H TN survival studies
A previous study demonstrated that newborn laboratory mice were susceptible to infection with HTNV,
and the mortality by HTNV was age-dependent and
with an inoculum 10 LD 50 , was 100% in m ice infected within 72 h of birth (Kim and McKee, 1985).
Therefore, animal manipulations with HTNV under this
study were performed using newborn mice less than
24 h after birth (Day 1), and as a control, mice 3
days after birth (Day 3). Outbred ICR pregnant mice
were obtained to produce newborn mice (Sam Tako
Inc., Korea). To evaluate the effects of blocking antibodies, newborn mice were injected intraperitoneally
(i.p.) with a hamster anti-mouse integrin β3 (CD61)
chain-specific antibody, hamster anti-mouse integrin
αv (CD 51) chain-specific antibody or hamster antimouse integrin β1 (CD29) chain-specific antibody
(PharMingen,) or 50 µl of an mouse anti-HTNV sera
prepared as previously described (Lee et al., 1985)
or LM609 (Chemicon), a murine anti-human αv β3
monoclonal antibody that does not cross-react with
the murine vitronectin receptor (Cheresh, 1987).
Following adoptive transfer of antibodies of 5-40 µg
(2.8-22.8 mg/kg body weight), the mice were challenged 16-18 h later by i.p. injection of 2,000 PFU
of HTNV, strain 76-118. Additional newborn pups
were pre-treated instead with a small-molecule, nonpeptide-selective αv β3 -receptor antagonist XT-199 [3(3-(3-(4, 5-dihydroimidazol 2-ylamino) propyloxylisoxazol-5-yl) carbonylamino)-2-(phenylsulfonylamino) propionic acid, DuPont Pharmaceuticals Co.]. These
pups received i.p. 5 mg/kg of XT-199 on the day
before viral infection followed by 10 mg/kg of the
antagonist for an additional 14 days. For all groups,
survival rates were recorded for 5 weeks after
challenge. Each set of HTNV challenges were performed on groups of 10 cohorted pups and were
performed two or three times for each group. The
results shown are the mean of each experiment. All
animals were treated according to the Laboratory
Institute Animal Control Guideline in compliance with

National Institutes of Health-American Association of
Laboratory Animal Control Guidelines. All the animal
experiments were done in a BSL3 facility.

Indirect im m unofluorescence assay (IFA )
For these studies, mice were sacrificed at 3- to 4day intervals from days 4 to 35 (n = 2 per time point
per group) after viral infection. Organs were excised
o
aseptically and frozen at -70 C until examined. Blood
samples were collected at the same time. For detection of HTNV antigen in tissues, specimens were
embedded in a polyethylene glycol compound
(Tissue-Tek II, Miles Laboratories). Sections were cut
at 4 µm in a CryoCut II (Ames Cryostat microtome)
o
at 25 C and fixed in cold acetone. Prepared slides
were incubated with anti-HTNV mouse hyperimmune
ascitic fluid, then stained for indirect immunofluorescence with fluorescein isothiocyanate (FITC)-labeled
goat antimouse IgG (1:32 diluted, ICN/Cappel). Slides
were examined with a Carl Zeiss-standard microscope
with epifluorescence and FITC filter system (×400,
50W , Leitz Co.). IFA for blood samples was performed using HTNV infected Vero E6 cells as the
antigen (Jung et al., 2004). The IFA titers were expressed as the reciprocal of the highest dilution of
the antisera that resulted in a specific immunofluorescence in the cytoplasm of the infected cells.
S tatistical analysis
The Student's T test was use to assess the significance of the mean time of survival. Studies were
done on 10 animals tested in two to three separate
analyses.

R e su lts a n d D is cu ss io n
E stablishing a new born pup m odel for H TN V
infection
For control studies, newborn mice pups less than one
day old (Day 1) were injected with 500 PFU to 7,500
PFU HTNV per recipient. Viral doses ≥ 2,000 PFU
significantly decreased mice survival (Figure 1A), with
accompanying body weight reduction by day 12-14
after infection (data not shown). In contrast, inoculations with less than 1,500 PFU had minimal effects on survival. Mice survival was -60% at Day 14
using an innoculum of 2,000 PFU. Accordingly, 2,000
PFU per pup HTNV recipient dose was chosen for
the in vivo experiment as partial efficacy of receptor
blocking might be appreciated by longer survival.
This model depends on the age of the pups at the
time of HTNV infection. Inoculation with 2,000 PFU
HTNV, even after only three days after birth (Day 3),
did not significantly increase mortality over no HTNV
inoculation controls, with an 80% survival rate (Figure
1B). However, use of a viral dose of 5,000 PFU in
Day 3 mice decreased survival to 20% at 12-14 days
(Figure 1B). These findings suggest that the mice de-
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Figure 1. Percent survival rate of HTNV infected mice. Day 1 mice (10 per group) were intraperitoneally injected with (A) 1,000 ( △ ), 1,500 ( ▲ ),
2,000 ( □ ), 2,500 ( ■ ) and 5,000 PFU ( ▽ ) HTNV, respectively. Controls (-) were injected with PBS only without virus ( ○ ). (B) Day 3 mice
( △ ) or Day 5 mice injected with 5,000 PFU ( ▲ ). Controls (-) ( ○ ) were injected with PBS only without virus, and controls (+) ( ● ) were injected
with 2,000 PFU of HTNV. The survival rates of HTNV infected mice were calculated daily, and the experiment was terminated on days 35. Each symbol
shows mean survival value.

Table 1. Distribution of HTN viral antigen in tissue and development
of antibodies in blood. ICR mice were infected intraperitoneally with
40 µl of virus (2000 PFU). Two mice from each infected group were
killed on Days 7, 14, 21, 28, or 35 after infection for IFA test.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
IFA titer in
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Days (p.i.) Group
Organ
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ Blood
Brain
Lung Kidney
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Day 7
Day 1
+
+
＜16
Day 3
＜16
Day 14

Day 1
Day 3

+++
-

+++
-

++
-

≥64
＜16

Day 21
Day 3
2048
Day 28
Day 3
+
4096
Day 35
Day 3
+
2048
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Antigen scoring: 0, no positive cells; 1+, rare positive cells; 2+, few
positive cells; 3+, moderate number of positive cells; 4+, many positive
cells.

velop a protective immune mechanism by three days
of age and that the studies for the importance of the
αv β3 receptor on HTNV infection would need to be
carried out on Day 1 mice.
The distribution of viral antigen in target organs,
such as brain, lung and kidney, and the anti-HTN
antibody titered in blood were determined in the Day
1 and Day 3 animals infused with 2,000 PFU (Table
1). After inoculation with HTNV on Day 1, viral
antigen was detectable as early as Day 4 at low concentrations. Viral antigen levels peaked at a modest
titer (≥ 64) on Day 14 in most tissues rapidly followed
by the demise of the pups. These pups never de-

veloped a high titer of anti-HTNV antibody. In the
Day 3 m ice, none of the anim als developed detectable HTNV in their tissues, but did develop high
antibody titers (≥2,048), which peaked at Day 28.
The modest immune response in Day 1 animals may
explain the susceptibility of these anim als to HTNV
infection.

In vivo H TN infection blocking studies w ith anti-αv
and anti-β3 antibodies
The use of antibodies to block viral binding to a specific receptor has been used successfully to identify
receptors important in viral uptake (Greve et al.,
1989). Antibodies to β3 integrins and the high affinity
β3 integrin ligand, vitronectin, block in vitro infection
by pathogenic hantaviruses, but not to non-pathogenic
hantaviruses. It suggested that integrin-specific interactions could contribute to hantavirus diseases
(Gavrilovskaya et al., 1998; 1999). Thus, CHO cell
lines expressing recombinant αIIb β3 or αv β3 integrins,
dramatically enhanced the infectivity of HTNV of this
cell line. Pretreatment of CHO cell lines with antisera
to β3 integrins specifically reduced the number of cells
infected by HTNV by ＞ 90%. We, therefore, explored
whether such antibodies would affect the course of
HTNV infection in our newborn pup model and
provide new insights into its in vivo pathobiology.
Figure 2 shows the inhibitory effect on viral toxicity
of an i.p. infusion of the anti-mouse αv antibody preceding infection. Mice survival rate was not appreciably different after injections at the two lowest doses
of 1-2 µg (0.6-1.1 mg/kg body weight) (data not
shown), but was extended in the ≥ 5 µg (2.8-22.8
mg/kg body weight) treatment group. The effect peaked at 20 µg (11.4 mg/kg body weight) anti-αv antibody
per pup compared to animals infused with PBS alone
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Figure 2. Percent survival rate of HTNV infected mice with mAb-α v. Day
1 mice (10 per group) were intraperitoneally injected with 2000 PFU of
HTNV, after treatment of mAb-α v at concentrations of 5 ( △ ), 10 ( ▲ ),
20 ( □ ), and 40 ( ■ ) µg. Controls (-) ( ○ ) were not injected with
HTN, and controls (+) ( ● ) were injected with 2000 PFU of HTNV, but
no antibody. The survival rates of HTNV infected mice were calculated
daily, and the experiment was terminated on Day 35. Each symbol shows
mean survival value.

Figure 3. Percent survival rate of HTNV infected mice with anti-murine
β 3 antibody. Mice (10 mice per group, Day 1) were intraperitoneally
injected with 2000 PFU of HTNV, after treatment of mAb-β 3 at
concentrations of 5 ( △ ), 10 ( ▲ ), 20 ( □ ), and 40( ■ ) µg. Controls
(-) ( ○ ) were not injected with HTNV, and controls (+) ( ● ) were injected
with 2000 PFU of HTNV, but no antibody. The survival rates of HTNV
infected mice were calculated daily, and the experiment was terminated
on Day 35. Each symbol shows mean survival value.

Figure 4. Percent survival rate of HTNV infected mice under various
conditions. Mice (10 mice per group, Day 1) were studied as follows:
(A) Controls (-) ( ○ ) were not injected with HTN, and controls (+)
( ● ) were injected with 2000 PFU of HTNV, but no antibody. Animals
were injected with HTNV after treatment of combinations of antibodies
at concentrations of [each 10 µg of α v and β 3 ( △ ), each 20 µg of
α v and β 3 ( ▲ )], (B) Controls (-) ( ○ ) were not injected with HTNV,
and controls (+) ( ● ) were injected with 2000 PFU of HTNV, but no
antibody. Animals were injected with HTNV while being treated with
XT-199( ▲ ). (C) Controls (-) ( ○ ) were not injected with HTNV, and
controls (+) ( ● ) were injected with 2000 PFU of HTNV, but no antibody.
Animals were injected with HTNV after treatment with anti-HTNV sera
[anti-HTNV ( △ )] or LM609 ( ▲ ). The survival rates of HTNV infected
mice were calculated daily, and the experiment was terminated on day
35. Each symbol shows mean survival value.

Integrin β 3 as receptor of Hantaan virus cellular entry

(survival: 18.4 ± 0.9 days vs. 14.2 ± 1.1 days, respectively, P ＜ 0.01) or to anim als infused with
LM609, a murine anti-human αv β3 mAb that does not
react with murine αvβ3 (Cheresh, 1987) (survival: 18.4
± 0.9 days vs. 14.0 ± 0.9 days, respectively, P ＜
0.01).
An anti-murine β3 antibody was used in similar
mice survival studies (Figure 3). At the lowest doses
of 1 and 2 µg (0.6-1.1 mg/kg body weight) of antibody
injected per pup, survival was nearly indistinguishable
from that of pups injected with PBS (data not shown).
However at higher antibody doses, pups survived for
a longer period of time after HTNV infection, although
all treated mice still succumbed by Day 23. This
attenuation of the death rate was maximal at 10 µg
(5.7 mg/kg body weight) of the anti-CD61 β3 antibody
per pup (survival: 19.7 ± 1.5 days vs. 14.2 ± 1.1
days, respectively, P ＜ 0.01).
There is no murine integrin αv β3 complex-specific
antibody currently available. To further examine the
significance of the integrin αv β3 for HTN viral
infectivity, combined treatment with the anti-mouse av
and anti-mouse β3 antibodies was tested (Figure 4A).
W e anticipated that combined therapy would have a
synergistic or at least an additive protective effect.
Neither was seen. At two different doses of the two
antibodies, survival was prolonged for several days
compared to control animals, but no difference was
noted compared to treatment with the individual antibodies.
It is evident that antibody does not inhibit the virus
entry in a dose dependent manner. An important
finding of our studies is that in the presence of high
concentration of antibodies, blocking of HTNV binding
and infection by antibodies was relatively inefficient
(Figure 3 and 4A). This may be because antibody
have unexpected side effects by steric hinderance of
other ligand-receptor interactions or only partial
inhibition of the integrin signaling.
Histological samples were also examined. No difference in tissue histology for HTN viral infection was
seen for the Day 1 mice for any of the blocking
studies (data not shown). Additionally, there was no
difference in the anti-HTNV titers that developed (data
not shown). W e, therefore, could not correlate the
observed improvement in survival with the animals
mounting a significant immune response.

B locking the αv β3 receptor using XT-199
The observations of a limited improvement in survival
using the above anti-αv and anti-β3 blocking antibodies suggest that HTN viral infection is more complex than simply cell entry using the αvβ3 receptor and
that one can achieve a significant, but limited, interruption in HTNV infection by blocking the αv β3
receptor in the infectious process in newborn pups.
This conclusion is supported by additional studies
using a specific αv β3-integrin receptor inhibitor XT-199
at its known blocking dose (Bishop et al., 2001). In
these studies, XT-199 was begun prior to HTNV
infection and given for 14 days. These treated pups
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showed a significant improvement in survival rate
compared to controls (Figure 4B) that was comparable to the improvement in survival seen with the
blocking antibody studies (Figure 4A).

A bility of H TN antibody against H TN infection
Our data in Table 1 suggest that by Day 3 of life,
murine pups are protected from HTN infection. These
animals coincidentally develop high titers of antiHTNV antibodies. W e wondered whether it is these
antibodies that are the critical difference between Day
1 and Day 3 pups in our HTNV infection model and
whether the limited ability of antibodies to murine αvβ3
to protect animals may be secondary to viral infection
by other mechanisms. We, therefore, i.p. injected antiHTNV antibody on Day 1 of life prior to HTN infection
with 2,000 PFU using an anti-HTNV titer ≥2,048
(Figure 4C). Anti-HTNV sera not only prolonged the
overall survival rate from controls (27.0 ± 2.7 days
vs. 14.2 ± 1.1 days, respectively, P ＜ 0.01), it also
resulted in the survival of 20% of the animals.
Although mortality was still high, no survivors were
ever seen in any tested animals using αv or β3 receptor blocking antibodies or drug.
These studies suggest that a major part of the
reason why Day 3 mice may be protected from HTNV
infection may indeed be their ability to mount a rapid
and vigorous anti-viral antibody response. These data
show that an antibody approach can be protective
against death in this model. However, the inability of
antibodies and drugs directed at the vitronectin receptor to fully protect offsprings from HTNV-related
death suggest that this virus may have an alternative
mechanism of cell entry during in vivo infection.

Figure 5. Percent survival rate of HTNV or PHV infected mice with
anti-murine β 1 antibody. Mice (10 mice per group, Day 1) were
intraperitoneally injected with 2000 PFU of HTNV or PHV, after treatment
of mAb-β 1 at concentrations of 10 ( □ ), 2 ( ■ ) µg with HTNV, and
10 ( ▲ ) µg with PHV. Controls (-) ( ○ ) were not injected with viruses,
and controls (+) were injected with 2000 PFU of HTNV ( ● ) or PHV
( △ ). The survival rates of HTNV infected mice were calculated daily,
and the experiment was terminated on Day 35. Each symbol shows mean
survival value.
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Such similar cases of partial inhibition have been
known. Adenovirus papillomavirus, FMDV, or coxsackievirus are the examples. Anti-integrin antibodies
alone can not bring about complete inhibition of
cellular entry into these organisms. These viruses,
which also enter cells via αv β3 integrins, have been
reported to use additional cell surface receptors
(Wickham et al., 1993; Roivainen et al., 1994; Huang
et al., 1996; Evander et al., 1997; Neff et al., 1998).
Other viruses have been reported to utilize multiple
RGD-dependent integrins to initiate infection (Triantafilou et al., 2001). RGD ligand motifs recognized by
αvβ3 and αIIbβ3 integrins are absent from all hantavirus
proteins. Like that of rotaviruses, their entry is not
blocked by RGD peptides, indicating that their interaction with the β3 chain is independent of the
integrin binding to physiologic ligands (Gavrilovskaya
et al., 1999; Guerrero et al., 2000). Certainly, similar
null
HTNV infection studies using the described β3
mouse (Hodivala-Dilke et al., 1999) would further
support our model, but these animals are presently
not available. Furthermore, because of their bleeding
diathesis may be problematic for doing i.p. injections.

Possibility of other integrins involved in H TN V
infection
We, therefore, were interested in testing other receptors, focusing on related integrins. The in vitro observations that the nonpathogenic PHV cellular entry is
associated with β1 integrin (Gavrilovskaya et al.,
1999), suggest that HTNV infection might be able to
use other integrins for cell entry in vivo. We tested
the possibility of whether β1 integrins may be involved
in HTNV infection. An anti-murine β1 antibody was
used in mice survival studies against HTNV or PHV
infection (Figure 5). At doses of 10 and 20 µg
(5.7-11.4 mg/kg body weight) of antibody injected per
pup, survival in Day 1 mice after standard HTNV
infection was maximal (18.5 ± 1.1 days and 19.0 ±
1.2 days, respectively, P ＜ 0.01). Days of survival
rate at 20 µg of the anti-β1 antibody per pup was
significantly prolonged compared to animals infused
with PBS alone (19.0 ± 1.2 days vs. 15.0 ± 1.4
days, respectively, P ＜ 0.01). The prolongation of
survival after anti-β1 antibodies suggest that HTNV
infection is partly mediated through integrin β1
receptors as well as through β3 receptors in vivo.
In summary, these studies indicate that hantaviruses clearly utilize the αv β3 receptor for viral entry
in vivo. These studies also suggest that this may not
be the only mechanism by which hantaviruses enter
cells in a living organism. Our data would, therefore,
predict that blocking strategies directed against the
αv β3 receptor in the clinical care of HTNV infections
may not be as efficacious as therapy directed against
the HTN virion itself. Our data also suggest that β1
intergrins are another family of receptors through
which HTNV can enter cells in vivo. Combined studies
show that the blockade of β1 and β3 is not synergistic
(data not shown). Collectively, these data will contribute substantially to precise pathogenetic approach

toward understanding the mechanism of virulence.
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